Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess

A therapeutic agent, inhalation technology, used in the field of therapeutic agents for aspiration pneumonia, pulmonary suppuration or lung abscess

Pending Publication Date: 2020-03-17
KYORIN PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are reports of observed therapeutic efficacy for moxifloxacin and pazufloxacin (Non-Patent Documents 3 to 4 and Non-Patent Document 7), they have not been established as effective treatments so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
  • Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
  • Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0091] Hereinafter, the present invention will be described in more detail by showing examples, but the scope of the present invention is not limited by these examples.

[0092] According to the method disclosed in International Publication No. WO 2016 / 195014, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]-6 - 150 mg injection of fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (hereinafter also referred to as Investigational New Drug A) .

[0093] "150mg" in 150mg injection indicates that in 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-( 2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride is the weight in terms of free form. In the preparation of injections, 162.5 mg (converted to free form: 150 mg) of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]- 6-Fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate hydrochloride. (Te...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to a safer and more efficient therapeutic agent for respiratory tract infections. A therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess, the agent containing as an active ingredient 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The present invention relates to a therapeutic agent for aspiration pneumonia, lung suppuration or lung abscess. Background technique [0002] Since the development of norfloxacin, quinolone carboxylic acid antibacterial agents called new quinolones have been developed all over the world, and many new quinolone antibacterial agents are currently widely used as therapeutic drugs for infectious diseases. [0003] Meanwhile, a quinolonecarboxylic acid derivative represented by the general formula (1) has been disclosed by the applicant (Patent Document 1). [0004] [Formula 1] [0005] [0006] In formula (1), R 1 Represents an alkyl group with 1 to 6 carbon atoms optionally substituted by one or more halogen atoms; a cycloalkyl group with 3 to 6 carbon atoms optionally substituted by one or more halogen atoms; or aryl A group or a heteroaryl group, which is optionally substituted by one or more identical or different substituents selected from halo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61P11/00A61P31/04
CPCA61K31/4709A61P11/00A61P31/04
Inventor 小田岛正明谷冈幸代子须之内孝明田渊亚沙子
Owner KYORIN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com